Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases

Abstract

In C. elegans, genetic and biochemical data indicate that the Cbl homolog Sli-1 attenuates Let-23 (EGFR) signaling. To investigate whether c-Cbl might have a role in mammalian growth factor-mediated mitogenic signaling, we microinjected NIH3T3 mouse fibroblasts with expression plasmids encoding wt and G306ECbl (a `loss of function' mutant identified in C. elegans). We observed inhibition of PDGF BB- and EGF-induced DNA synthesis by wt Cbl but not the mutant. Microinjection of two different affinity purified polyclonal antisera against Cbl boosted a suboptimal PDGF-stimulated mitogenic response. The inhibition of both PDGF BB- and EGF-induced DNA synthesis by wt Cbl was reversed by co-expression with Myc but not with Fos. DNA synthesis initiated by constitutively activated Src was also blocked by Cbl expression, but curiously by the G306E mutant as well. These data are all consistent with the proposition that Cbl negatively affects mitogenic signaling in mammalian fibroblasts.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Barone MV and Courtneidge SA. . 1995 Nature 378: 509–512.

  • Blake TJ, Heath KG and Langdon WY. . 1993 EMBO J. 12: 2017–2026.

  • Blake TJ, Shapiro M, Morse III HC and Langdon WY. . 1991 Oncogene 6: 653–657.

  • Bonita DP, Miyake S, Lupher Jr ML, Langdon WY and Band H. . 1997 Mol. Cell Biol. 17: 4597–4610.

  • Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JAM, Lammers J-WJ, Koenderman L and de Groot RP. . 1996 J. Biol. Chem. 271: 13221–13227.

  • Fukazawa T, Reedquist KA, Trub T, Soltoff S, Panchamoorthy G, Druker B, Cantley L, Shoelson SE and Band H. . 1995 J. Biol. Chem. 270: 19141–19150.

  • Galisteo ML, Dikic I, Batzer AG, Langdon WY and Schlessinger J. . 1995 J. Biol. Chem. 270: 20242–20245.

  • Hime GR, Dhungat MP, Ng A and Bowtell DD. . 1997 Oncogene 14: 2709–2719.

  • Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC and Lipkowitz S. . 1995 Oncogene 10: 2367–2377.

  • Kypta RM, Goldberg Y, Ulug ET and Courtneidge SA. . 1990 Cell 62: 481–492.

  • Langdon WY, Hartley JW, Klinken SP, Ruscetti SK and Morse III HC. . 1989 Proc. Natl. Acad. Sci. USA 86: 1168–1172.

  • Lupher Jr ML, Reedquist KA, Miyake S, Langdon WY and Band H. . 1996 J. Biol. Chem. 271: 24063–24068.

  • Lupher Jr ML, Songyang Z, Shoelson SE, Cantley LC and Band H. . 1997 J. Biol. Chem. 272: 33140–33144.

  • Meisner H, Daga A, Buxton J, Fernandez B, Chawla A, Banerjee U and Czech MP. . 1997 Mol. Cell. Biol. 17: 2217–2225.

  • Meng W, Sawasdikosol S, Burakoff SJ and Eck MJ. . 1999 Nature 398: 84–90.

  • Miyake S, Lupher Jr ML, Andoniou CE, Lill NL, Ota S, Douillard P, Rao N and Band H. . 1997 Crit. Rev. Onco. 8: 189–218.

  • Miyake S, Lupher Jr ML, Druker B and Band H. . 1998 Proc. Natl. Acad. Sci. USA 95: 7927–7932.

  • Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CB, Langdon WY and Bowtell DDL. . 1998 Mol. Cell. Biol. 18: 4872–4882.

  • Ota Y and Samelson LE. . 1997 Science 276: 418–420.

  • Rellahan BL, Graham LJ, Stoica B, DeBell KE and Bonvini E. . 1997 J. Biol. Chem. 272: 30806–30811.

  • Richardson A and Parsons T. . 1996 Nature 380: 538–540.

  • Roche S, Alonso G, Kazlauskas A, Dixit VM, Courtneidge SA and Pandey A. . 1998 Curr. Biol. 8: 975–978.

  • Roche S, McGlade J, Jones M, Gish GD, Pawson T and Courtneidge SA. . 1996 EMBO J. 15: 4940–4948.

  • Smit L and Borst J. . 1997 Crit. Rev. Onco. 8: 359–379.

  • Superti-Furga G, Jonsson K and Courtneidge SA. . 1996 Nature Biotech. 14: 600–605.

  • Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB and Baron R. . 1996 Nature 383: 528–531.

  • Thien CB and Langdon WY. . 1997 Oncogene 14: 2239–2249.

  • Tsygankov AY, Mahajan S, Fincke JE and Bolen JB. . 1996 J. Biol. Chem. 271: 27130–27137.

  • Ueno H, Sasaki K, Miyagawa K, Honda H, Mitani K, Yazaki Y and Hirai H. . 1997 J. Biol. Chem. 272: 8739–8743.

  • Yishimura T, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T and Miyajima A. . 1995 EMBO J. 14: 2816–2826.

  • Yoon CH, Lee J, Jongeward GD and Sternberg PW. . 1995 Science 269: 1102–1105.

Download references

Acknowledgements

The authors wish to thank Dr Wallace Y Langdon for providing the wild-type and G306E mutant HA-tagged Cbl cDNAs.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Broome, M., Galisteo, M., Schlessinger, J. et al. The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. Oncogene 18, 2908–2912 (1999). https://doi.org/10.1038/sj.onc.1202873

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1202873

Keywords

This article is cited by

Search

Quick links